Loading clinical trials...
Loading clinical trials...
A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
Conditions
Interventions
Levosimendan
Matching Placebo
Locations
16
United States
Stanford Healthcare
Stanford, California, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
Tufts Medical Center
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
University of Minnesota Medical Center
Minneapolis, Minnesota, United States
Start Date
November 14, 2018
Primary Completion Date
April 7, 2020
Completion Date
April 7, 2020
Last Updated
November 20, 2024
NCT03549559
NCT03269630
NCT06937320
NCT03387813
NCT03184311
NCT03317314
Lead Sponsor
Tenax Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions